ES2125567T3 - Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña. - Google Patents

Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.

Info

Publication number
ES2125567T3
ES2125567T3 ES95307000T ES95307000T ES2125567T3 ES 2125567 T3 ES2125567 T3 ES 2125567T3 ES 95307000 T ES95307000 T ES 95307000T ES 95307000 T ES95307000 T ES 95307000T ES 2125567 T3 ES2125567 T3 ES 2125567T3
Authority
ES
Spain
Prior art keywords
prevention
treatment
antagonist
combination
tachiquinine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95307000T
Other languages
English (en)
Inventor
Marlene Lois Cohen
Kirk Willis Johnson
Lee Alan Phebus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2125567T3 publication Critical patent/ES2125567T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION PROPORCIONA METODOS PARA EL TRATAMIENTO O PREVENCION DE MIGRAÑAS QUE COMPRENDE LA ADMINISTRACION A UN MAMIFERO QUE LO NECESITE UNA COMBINACION DE UN ANTAGONISTA RECEPTOR DE TAQUIQUININA Y UN AGONISTA DE SEROTONINA. ESTA ADMINISTRACION PUEDE SER CONCURRENTE O SECUENCIAL, CON CUALQUIERA DE LAS DOS ACTIVIDADES SIENDO ADMINISTRADA PRIMERO.
ES95307000T 1994-10-05 1995-10-03 Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña. Expired - Lifetime ES2125567T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/318,391 US5744482A (en) 1994-10-05 1994-10-05 Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine

Publications (1)

Publication Number Publication Date
ES2125567T3 true ES2125567T3 (es) 1999-03-01

Family

ID=23237987

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95307000T Expired - Lifetime ES2125567T3 (es) 1994-10-05 1995-10-03 Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.

Country Status (12)

Country Link
US (1) US5744482A (es)
EP (1) EP0710479B1 (es)
AT (1) ATE175347T1 (es)
AU (1) AU4130196A (es)
DE (1) DE69507112T2 (es)
DK (1) DK0710479T3 (es)
ES (1) ES2125567T3 (es)
GR (1) GR3029666T3 (es)
IL (1) IL115451A0 (es)
SI (1) SI0710479T1 (es)
WO (1) WO1996011000A1 (es)
ZA (1) ZA958173B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
ATE300308T1 (de) * 1994-12-12 2005-08-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und spasmen an einer wunde
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
AU5966196A (en) * 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
WO1998011895A1 (en) * 1996-09-18 1998-03-26 Eli Lilly And Company A method for the prevention of migraine
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
DE19917347A1 (de) * 1999-04-16 2000-11-09 Gsf Forschungszentrum Umwelt Verfahren und Vorrichtung zum trockenen Anbringen von Substanzen an inhalierbare pulverförmige Trägerstoffe
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US20100210554A1 (en) * 2007-09-11 2010-08-19 Dorian Bevec Therapeutic uses of gastrin- 1 and g- pen-grgdspca

Also Published As

Publication number Publication date
IL115451A0 (en) 1995-09-28
EP0710479A1 (en) 1996-05-08
AU4130196A (en) 1996-05-02
ATE175347T1 (de) 1999-01-15
DE69507112D1 (de) 1999-02-18
SI0710479T1 (en) 1999-06-30
DK0710479T3 (da) 1999-08-30
GR3029666T3 (en) 1999-06-30
ZA958173B (en) 1997-04-01
WO1996011000A1 (en) 1996-04-18
EP0710479B1 (en) 1999-01-07
US5744482A (en) 1998-04-28
DE69507112T2 (de) 1999-06-10

Similar Documents

Publication Publication Date Title
ES2125567T3 (es) Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
AR008444A1 (es) Empleo de antagonistas de leptina para el tratamiento de la resistencia a la insulina en diabetes del tipo ii
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
BR0109837A (pt) Composição farmacêutica para o tratamento da dor aguda, crÈnica e/ou neuropática e enxaquecas
BR9106977A (pt) Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero
BRPI0518282A2 (pt) uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
ES2171768T3 (es) Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
EA200300183A1 (ru) Новое сочетание агониста (5-th2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
FI974268A (fi) Flavanolignaanien käyttö lääkkeiden, joilla on lisääntymistä torjuvaa vaikutusta kohdussa, munasarjoissa ja rintarauhasessa, valmistamiseksi
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
ES2174337T3 (es) Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
AR023597A1 (es) Utilizacion del saredutant y de sus sales farmaceuticamente aceptables para la preparacion de medicamentos utiles en el tratamiento o la prevencion delconjunto de los trastornos del humor, de los trastornos de adaptacion o de los trastornos mixtos ansiedad-depresion
UY26376A1 (es) Combinaciones sinteticas de un antagonista de nk1 y un analogo estructural de gaba
BRPI0415651A (pt) métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica
DK0799618T3 (da) Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
MX9304075A (es) Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 710479

Country of ref document: ES